DD144055A5 - Verfahren zur herstellung neuer aminothiazole - Google Patents

Verfahren zur herstellung neuer aminothiazole Download PDF

Info

Publication number: DD144055A5
Authority: DD; German Democratic Republic
Prior art keywords: phenyl; carbon atoms; group; compounds; mol
Prior art date: 1978-06-02

Application number

DD79213371A

Other languages

German (de)

English (en)

Inventor

Joseph G Lombardino

Jasjit S Bindra

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-06-02

Filing date

1979-06-01

Publication date

1980-09-24

1979-06-01 Application filed by Pfizer filed Critical Pfizer

1980-09-24 Publication of DD144055A5 publication Critical patent/DD144055A5/de

Links

238000000034 method Methods 0.000 title claims description 16
RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 title description 17
229950003476 aminothiazole Drugs 0.000 title description 7
150000001875 compounds Chemical class 0.000 claims description 46
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
125000004432 carbon atom Chemical group C* 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 16
-1 monosubstituted phenyl Chemical group 0.000 claims description 15
UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 12
238000006243 chemical reaction Methods 0.000 claims description 12
229910052739 hydrogen Inorganic materials 0.000 claims description 11
239000001257 hydrogen Substances 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 10
125000001424 substituent group Chemical group 0.000 claims description 10
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
229910052794 bromium Inorganic materials 0.000 claims description 9
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
239000000460 chlorine Substances 0.000 claims description 8
229910052801 chlorine Inorganic materials 0.000 claims description 8
229910052731 fluorine Inorganic materials 0.000 claims description 8
239000011737 fluorine Substances 0.000 claims description 8
125000001544 thienyl group Chemical group 0.000 claims description 8
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
125000002541 furyl group Chemical group 0.000 claims description 5
150000003585 thioureas Chemical class 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 49
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 description 20
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 19
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 19
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
238000010992 reflux Methods 0.000 description 18
229910052757 nitrogen Inorganic materials 0.000 description 17
239000000243 solution Substances 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
239000007787 solid Substances 0.000 description 14
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 12
230000000694 effects Effects 0.000 description 12
238000004458 analytical method Methods 0.000 description 11
239000003814 drug Substances 0.000 description 11
238000001816 cooling Methods 0.000 description 10
108010062580 Concanavalin A Proteins 0.000 description 9
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
229910000041 hydrogen chloride Inorganic materials 0.000 description 9
239000000575 pesticide Substances 0.000 description 9
229940079593 drug Drugs 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 description 7
239000002904 solvent Substances 0.000 description 7
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 6
235000010418 carrageenan Nutrition 0.000 description 6
229920001525 carrageenan Polymers 0.000 description 6
229960001614 levamisole Drugs 0.000 description 6
239000003921 oil Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
206010039073 rheumatoid arthritis Diseases 0.000 description 6
BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical class NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 5
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
229940121363 anti-inflammatory agent Drugs 0.000 description 5
239000002260 anti-inflammatory agent Substances 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
239000007789 gas Substances 0.000 description 5
239000003960 organic solvent Substances 0.000 description 5
238000001953 recrystallisation Methods 0.000 description 5
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 4
206010030113 Oedema Diseases 0.000 description 4
241000700159 Rattus Species 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
150000002431 hydrogen Chemical class 0.000 description 4
230000028993 immune response Effects 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000607479 Yersinia pestis Species 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
239000012458 free base Substances 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
DYFFAVRFJWYYQO-UHFFFAOYSA-N n-methyl-n-phenylaniline Chemical class C=1C=CC=CC=1N(C)C1=CC=CC=C1 DYFFAVRFJWYYQO-UHFFFAOYSA-N 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
229940104230 thymidine Drugs 0.000 description 3
210000001541 thymus gland Anatomy 0.000 description 3
OFVGPHQYOCKLLM-UHFFFAOYSA-N 2-phenylethylthiourea Chemical compound NC(=S)NCCC1=CC=CC=C1 OFVGPHQYOCKLLM-UHFFFAOYSA-N 0.000 description 2
RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010030124 Oedema peripheral Diseases 0.000 description 2
230000002456 anti-arthritic effect Effects 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
UCGFRIAOVLXVKL-UHFFFAOYSA-N benzylthiourea Chemical compound NC(=S)NCC1=CC=CC=C1 UCGFRIAOVLXVKL-UHFFFAOYSA-N 0.000 description 2
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000679 carrageenan Substances 0.000 description 2
229940113118 carrageenan Drugs 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
238000001035 drying Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
SKHIBNDAFWIOPB-UHFFFAOYSA-N hydron;2-phenylethanamine;chloride Chemical compound Cl.NCCC1=CC=CC=C1 SKHIBNDAFWIOPB-UHFFFAOYSA-N 0.000 description 2
230000004957 immunoregulator effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
XHAHWNWJFYVXIU-UHFFFAOYSA-N n'-phenylethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNC1=CC=CC=C1 XHAHWNWJFYVXIU-UHFFFAOYSA-N 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 2
229940117803 phenethylamine Drugs 0.000 description 2
229940048346 phenethylamine hydrochloride Drugs 0.000 description 2
229960002895 phenylbutazone Drugs 0.000 description 2
VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
NZYMHENLAOOTLV-UHFFFAOYSA-N thiophen-2-ylmethylazanium;chloride Chemical compound Cl.NCC1=CC=CS1 NZYMHENLAOOTLV-UHFFFAOYSA-N 0.000 description 2
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
WLOXAUTXAOGCCI-UHFFFAOYSA-N 1,3-dibenzhydrylthiourea Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)NC(=S)NC(C=1C=CC=CC=1)C1=CC=CC=C1 WLOXAUTXAOGCCI-UHFFFAOYSA-N 0.000 description 1
ORECNKBJIMKZNX-UHFFFAOYSA-N 1,3-thiazol-3-ium;chloride Chemical compound Cl.C1=CSC=N1 ORECNKBJIMKZNX-UHFFFAOYSA-N 0.000 description 1
DDGHBOLOCQWPKE-UHFFFAOYSA-N 1,3-thiazole;hydrobromide Chemical compound [Br-].C1=CSC=[NH+]1 DDGHBOLOCQWPKE-UHFFFAOYSA-N 0.000 description 1
SFCCOHHWKRVDHH-UHFFFAOYSA-N 1-(2-bromophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=CC=C1Br SFCCOHHWKRVDHH-UHFFFAOYSA-N 0.000 description 1
SYGLPNDHSSTGNF-UHFFFAOYSA-N 2-anilinoethylthiourea Chemical compound N(C1=CC=CC=C1)CCNC(=S)N SYGLPNDHSSTGNF-UHFFFAOYSA-N 0.000 description 1
ZFFBIQMNKOJDJE-UHFFFAOYSA-N 2-bromo-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Br)C(=O)C1=CC=CC=C1 ZFFBIQMNKOJDJE-UHFFFAOYSA-N 0.000 description 1
RXDYOLRABMJTEF-UHFFFAOYSA-N 2-chloro-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(Cl)C(=O)C1=CC=CC=C1 RXDYOLRABMJTEF-UHFFFAOYSA-N 0.000 description 1
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
UXZPFPLPTODLCU-UHFFFAOYSA-N 4,5-diphenyl-n-(2-phenylethyl)-1,3-thiazol-2-amine Chemical compound N=1C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)SC=1NCCC1=CC=CC=C1 UXZPFPLPTODLCU-UHFFFAOYSA-N 0.000 description 1
NTUXEUGLSZFNPX-UHFFFAOYSA-N 5-methyl-4-phenyl-n-(2-phenylethyl)-1,3-thiazol-2-amine Chemical compound N=1C(C=2C=CC=CC=2)=C(C)SC=1NCCC1=CC=CC=C1 NTUXEUGLSZFNPX-UHFFFAOYSA-N 0.000 description 1
WCXJDDPHWIKWRN-UHFFFAOYSA-N 5-methyl-4-phenyl-n-(2-phenylethyl)-1,3-thiazol-2-amine;hydrobromide Chemical compound Br.N=1C(C=2C=CC=CC=2)=C(C)SC=1NCCC1=CC=CC=C1 WCXJDDPHWIKWRN-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000002585 base Substances 0.000 description 1
CIHWJRSPVJBHGT-UHFFFAOYSA-N benzhydrylazanium;chloride Chemical compound Cl.C=1C=CC=CC=1C(N)C1=CC=CC=C1 CIHWJRSPVJBHGT-UHFFFAOYSA-N 0.000 description 1
150000003939 benzylamines Chemical class 0.000 description 1
XKXHCNPAFAXVRZ-UHFFFAOYSA-N benzylazanium;chloride Chemical compound [Cl-].[NH3+]CC1=CC=CC=C1 XKXHCNPAFAXVRZ-UHFFFAOYSA-N 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical group C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
WEEYMMXMBFJUAI-UHFFFAOYSA-N fanetizole Chemical compound N=1C(C=2C=CC=CC=2)=CSC=1NCCC1=CC=CC=C1 WEEYMMXMBFJUAI-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
125000004175 fluorobenzyl group Chemical group 0.000 description 1
125000001207 fluorophenyl group Chemical group 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
XSWHIPZJAMCLRZ-UHFFFAOYSA-N furan-2-ylmethylthiourea Chemical compound NC(=S)NCC1=CC=CO1 XSWHIPZJAMCLRZ-UHFFFAOYSA-N 0.000 description 1
DDRPCXLAQZKBJP-UHFFFAOYSA-N furfurylamine Chemical compound NCC1=CC=CO1 DDRPCXLAQZKBJP-UHFFFAOYSA-N 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
229910000039 hydrogen halide Inorganic materials 0.000 description 1
239000012433 hydrogen halide Substances 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
229940124644 immune regulator Drugs 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000036046 immunoreaction Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000000203 mixture Substances 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
OCIDXARMXNJACB-UHFFFAOYSA-N n'-phenylethane-1,2-diamine Chemical compound NCCNC1=CC=CC=C1 OCIDXARMXNJACB-UHFFFAOYSA-N 0.000 description 1
JRFFAPQYMPSJBZ-UHFFFAOYSA-N n-(2-phenylethyl)-1,3-thiazol-2-amine Chemical compound N=1C=CSC=1NCCC1=CC=CC=C1 JRFFAPQYMPSJBZ-UHFFFAOYSA-N 0.000 description 1
QSLBXMRJPQRVER-UHFFFAOYSA-N n-benzyl-1,3-thiazol-2-amine Chemical compound C=1C=CC=CC=1CNC1=NC=CS1 QSLBXMRJPQRVER-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
230000005004 positive regulation of lymphocyte proliferation Effects 0.000 description 1
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
229940116357 potassium thiocyanate Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical compound NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
- F16B—DEVICES FOR FASTENING OR SECURING CONSTRUCTIONAL ELEMENTS OR MACHINE PARTS TOGETHER, e.g. NAILS, BOLTS, CIRCLIPS, CLAMPS, CLIPS OR WEDGES; JOINTS OR JOINTING
- F16B15/00—Nails; Staples
- F16B15/0023—Nail plates
- F16B2015/0076—Nail plates with provisions for additional fastening means, e.g. hooks, holes for separate screws or nails, adhesive

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DD79213371A 1978-06-02 1979-06-01 Verfahren zur herstellung neuer aminothiazole DD144055A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US91183078A	1978-06-02	1978-06-02

Publications (1)

Publication Number	Publication Date
DD144055A5 true DD144055A5 (de)	1980-09-24

Family

ID=25430923

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD79213371A DD144055A5 (de)	1978-06-02	1979-06-01	Verfahren zur herstellung neuer aminothiazole

Country Status (36)

Country	Link
JP (1)	JPS5936988B2 (cs)
AR (1)	AR226285A1 (cs)
AT (1)	AT373248B (cs)
AU (1)	AU511242B2 (cs)
BE (1)	BE876732A (cs)
CA (1)	CA1117949A (cs)
CH (1)	CH639653A5 (cs)
CS (1)	CS216927B2 (cs)
DD (1)	DD144055A5 (cs)
DE (1)	DE2922523C2 (cs)
DK (1)	DK150068C (cs)
EG (1)	EG14354A (cs)
ES (1)	ES481220A1 (cs)
FI (1)	FI68820C (cs)
FR (1)	FR2427333A1 (cs)
GB (1)	GB2022085B (cs)
GR (1)	GR73142B (cs)
HK (1)	HK66487A (cs)
HU (1)	HU180045B (cs)
IE (1)	IE48426B1 (cs)
IL (1)	IL57450A (cs)
IT (1)	IT1121238B (cs)
KE (1)	KE3459A (cs)
LU (1)	LU81349A1 (cs)
MY (1)	MY8500318A (cs)
NL (1)	NL178421C (cs)
NO (1)	NO150760C (cs)
NZ (1)	NZ190623A (cs)
PH (1)	PH17020A (cs)
PL (1)	PL117515B1 (cs)
PT (1)	PT69718A (cs)
SE (1)	SE438333B (cs)
SG (1)	SG56184G (cs)
SU (1)	SU843746A3 (cs)
YU (1)	YU40997B (cs)
ZA (1)	ZA792729B (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1982001481A1 (en) *	1980-10-24	1982-05-13	Ronald P Hansen	Dust mitigation system
US4511574A (en) *	1981-01-08	1985-04-16	Mitsui Toatsu Kagaku Kabushiki Kaisha	N-(4-Phenyl-2-thiazolyl)carbamate derivatives
JPS57136579A (en) *	1981-01-21	1982-08-23	Mitsui Toatsu Chem Inc	Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
JPS57116067A (en) *	1981-01-12	1982-07-19	Sankyo Kagaku Kk	Novel 8-quinolinesulfonyl derivative, its synthesis and use
WO1982002386A1 (en) *	1981-01-13	1982-07-22	Sakano Isao	Aminothiazole derivatives,process for their preparation,and medicinal composition containing same
WO1982002383A1 (fr) *	1981-01-13	1982-07-22	Sakano Isao	Nouveaux composes de thiazol, procede de preparation, et composition medicinale en contenant
JPS57154175A (en) *	1981-03-16	1982-09-22	Mitsui Toatsu Chem Inc	2-thiazoleamine derivative, its preparation, and drug composition comprising it
DE3227329A1 (de) *	1982-07-22	1984-01-26	Basf Ag, 6700 Ludwigshafen	Verfahren zur herstellung von 2-n,n-disubstituierten aminothiazolen
WO1986003203A1 (fr) *	1984-11-22	1986-06-05	Yoshitomi Pharmaceutical Industries, Ltd.	Derives de thienylthiazole
FR2581063B1 (fr) *	1985-04-30	1987-07-17	Chauvin Blache Lab	Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
JPS63152368A (ja) *	1986-06-03	1988-06-24	Sumitomo Pharmaceut Co Ltd	新規なアミノアゾ−ル誘導体およびその酸付加塩
JPH075579B2 (ja) *	1986-09-01	1995-01-25	吉富製薬株式会社	アミノチアゾ−ル化合物
JPH0753666B2 (ja) *	1987-09-14	1995-06-07	久光製薬株式会社	置換ジフェニルチアゾール誘導体からなる抗炎症剤
ES2111540T3 (es) *	1989-08-10	1998-03-16	Commw Scient Ind Res Org	Metodo para la produccion de una electrosuspension de microparticulas.
AU654125B2 (en) *	1991-03-07	1994-10-27	Hisamitsu Pharmaceutical Co., Inc.	Novel diphenylthyazole derivative
FR2692893B1 (fr) *	1992-06-24	1994-09-02	Sanofi Elf	Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
WO1996003392A1 (en) *	1994-07-27	1996-02-08	G.D. Searle & Co.	Substituted thiazoles for the treatment of inflammation
FR2754258B1 (fr)	1996-10-08	1998-12-31	Sanofi Sa	Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
ATE414079T1 (de)	2000-03-01	2008-11-15	Janssen Pharmaceutica Nv	2,4-disubstituierte thiazolyl derivate
EP1423113A4 (en) *	2001-08-13	2007-04-18	Phenex Pharmaceuticals Ag	NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
WO2003027094A2 (en) *	2001-09-26	2003-04-03	Bayer Pharmaceuticals Corporation	Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
RU2330839C2 (ru)	2002-01-11	2008-08-10	Санкио Компани, Лимитед	Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные
EP1555264A1 (en) *	2004-01-15	2005-07-20	Sireen AG	Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
TWI355934B (en)	2004-02-24	2012-01-11	Sankyo Co	Pharmaceutical composition for treatment or prophy
SG159561A1 (en)	2005-05-09	2010-03-30	Achillion Pharmaceuticals Inc	Thiazole compounds and methods of use
CN101421265A (zh)	2006-01-18	2009-04-29	安姆根有限公司	作为蛋白激酶b(pkb)抑制剂的噻唑化合物
AU2008276521B2 (en)	2007-07-17	2011-11-03	Amgen Inc.	Heterocyclic modulators of PKB
WO2009011871A2 (en)	2007-07-17	2009-01-22	Amgen Inc.	Thiadiazole modulators of pkb
US20130143927A1 (en) *	2011-06-10	2013-06-06	Calcimedica, Inc.	Compounds that modulate intracellular calcium
US20120316182A1 (en)	2011-06-10	2012-12-13	Calcimedica, Inc.	Compounds that modulate intracellular calcium
US9856240B2 (en)	2011-10-19	2018-01-02	Calcimedica, Inc.	Compounds that modulate intracellular calcium
CN110590785B (zh) *	2019-09-23	2021-02-02	武汉大学	一种氨基噻唑类化合物及其制备方法与抗肠道病毒71型的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3458526A (en) *	1966-09-26	1969-07-29	Upjohn Co	Certain 2-amino-4,5-bis(p-methoxyphenyl)thiazoles

1979
- 1979-04-30 DK DK177679A patent/DK150068C/da not_active IP Right Cessation
- 1979-05-23 GB GB7917872A patent/GB2022085B/en not_active Expired
- 1979-05-29 CH CH501679A patent/CH639653A5/fr not_active IP Right Cessation
- 1979-05-30 EG EG333/79A patent/EG14354A/xx active
- 1979-05-30 CS CS793728A patent/CS216927B2/cs unknown
- 1979-05-31 LU LU81349A patent/LU81349A1/xx unknown
- 1979-05-31 SE SE7904798A patent/SE438333B/sv not_active IP Right Cessation
- 1979-05-31 AU AU47634/79A patent/AU511242B2/en not_active Ceased
- 1979-05-31 CA CA000328805A patent/CA1117949A/en not_active Expired
- 1979-05-31 PH PH22588A patent/PH17020A/en unknown
- 1979-05-31 SU SU792773929A patent/SU843746A3/ru active
- 1979-05-31 IL IL57450A patent/IL57450A/xx unknown
- 1979-05-31 HU HU79PI679A patent/HU180045B/hu not_active IP Right Cessation
- 1979-05-31 YU YU1288/79A patent/YU40997B/xx unknown
- 1979-06-01 NO NO791831A patent/NO150760C/no unknown
- 1979-06-01 NZ NZ190623A patent/NZ190623A/en unknown
- 1979-06-01 PL PL1979216030A patent/PL117515B1/pl unknown
- 1979-06-01 BE BE0/195534A patent/BE876732A/xx not_active IP Right Cessation
- 1979-06-01 AT AT0401679A patent/AT373248B/de not_active IP Right Cessation
- 1979-06-01 ZA ZA792729A patent/ZA792729B/xx unknown
- 1979-06-01 AR AR276782A patent/AR226285A1/es active
- 1979-06-01 GR GR59240A patent/GR73142B/el unknown
- 1979-06-01 NL NLAANVRAGE7904337,A patent/NL178421C/xx not_active IP Right Cessation
- 1979-06-01 DE DE2922523A patent/DE2922523C2/de not_active Expired
- 1979-06-01 JP JP54068781A patent/JPS5936988B2/ja not_active Expired
- 1979-06-01 FI FI791754A patent/FI68820C/fi not_active IP Right Cessation
- 1979-06-01 FR FR7914164A patent/FR2427333A1/fr active Granted
- 1979-06-01 ES ES481220A patent/ES481220A1/es not_active Expired
- 1979-06-01 IT IT23228/79A patent/IT1121238B/it active
- 1979-06-01 DD DD79213371A patent/DD144055A5/de not_active IP Right Cessation
- 1979-06-01 PT PT69718A patent/PT69718A/pt unknown
- 1979-08-08 IE IE1069/79A patent/IE48426B1/en unknown
1984
- 1984-08-13 SG SG561/84A patent/SG56184G/en unknown
- 1984-09-24 KE KE3459A patent/KE3459A/xx unknown
1985
- 1985-12-30 MY MY318/85A patent/MY8500318A/xx unknown
1987
- 1987-09-17 HK HK664/87A patent/HK66487A/xx unknown

Also Published As

Publication number	Publication date
BE876732A (fr)	1979-12-03
DE2922523C2 (de)	1982-10-21
KE3459A (en)	1984-10-12
JPS54160369A (en)	1979-12-19
FR2427333A1 (fr)	1979-12-28
EG14354A (en)	1984-06-30
GB2022085B (en)	1983-01-12
AT373248B (de)	1983-12-27
DK150068B (da)	1986-12-01
GR73142B (cs)	1984-02-09
PL117515B1 (en)	1981-08-31
PT69718A (en)	1979-07-01
CH639653A5 (fr)	1983-11-30
CS216927B2 (en)	1982-12-31
IL57450A0 (en)	1979-09-30
NL178421B (nl)	1985-10-16
NO150760B (no)	1984-09-03
MY8500318A (en)	1985-12-31
FI791754A7 (fi)	1979-11-26
NL7904337A (nl)	1979-12-04
YU40997B (en)	1986-10-31
AU511242B2 (en)	1980-08-07
FR2427333B1 (cs)	1983-05-20
SU843746A3 (ru)	1981-06-30
FI68820B (fi)	1985-07-31
JPS5936988B2 (ja)	1984-09-06
SE7904798L (sv)	1979-12-03
AU4763479A (en)	1979-12-06
IT7923228A0 (it)	1979-06-01
NO791831L (no)	1979-12-04
ATA401679A (de)	1983-05-15
SE438333B (sv)	1985-04-15
IL57450A (en)	1982-11-30
DK150068C (da)	1987-06-29
IT1121238B (it)	1986-03-26
DK177679A (da)	1979-12-03
HK66487A (en)	1987-09-25
CA1117949A (en)	1982-02-09
FI68820C (fi)	1985-11-11
DE2922523A1 (de)	1979-12-06
LU81349A1 (fr)	1979-12-07
ZA792729B (en)	1981-03-25
NL178421C (nl)	1986-03-17
GB2022085A (en)	1979-12-12
IE48426B1 (en)	1985-01-23
IE791069L (en)	1979-12-02
AR226285A1 (es)	1982-06-30
ES481220A1 (es)	1980-09-01
NO150760C (no)	1984-12-12
NZ190623A (en)	1984-07-06
HU180045B (en)	1983-01-28
PL216030A1 (cs)	1980-03-10
YU128879A (en)	1982-10-31
PH17020A (en)	1984-05-11
SG56184G (en)	1985-03-08

Legal Events

Date	Code	Title	Description
1995-05-11	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE2922523C2 (de)	1982-10-21	Aminothiazole und diese enthaltende Arzneimitte l
DE2734070C2 (de)	1983-12-29	Aminoalkylfuranderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE2155558C2 (de)	1982-08-26	Trifluormethyl-diphenyl-imidazole und deren Verwendung
DE69219221T2 (de)	1997-11-20	Vanadium Komplexe, ihre Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten
DD200371A5 (de)	1983-04-20	Verfahren zur herstellung von 2,4-disubstituierten thiazolen
DD202426A5 (de)	1983-09-14	Verfahren zur herstellung von 1,2-diaminocyclobuten-3,4-dionen
DD233374A5 (de)	1986-02-26	Verfahren zur herstellung von 2-(n-subst.-guanidino)-4-heteroarylthiazole
DE2149249A1 (de)	1972-04-13	6-Arylpyrimidine
DE2619381B2 (de)	1977-10-06	2-(1-imidazolyl)-aethyl-thienylmethylaether und -thioaether, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE2916140A1 (de)	1979-10-31	1,3-diphenyl-2-iminoimidazolidine und 1,3-diphenyl-2-iminohexahydropyrimidine, verfahren zu ihrer herstellung und solche enthaltende arzneimittel
EP0110869B1 (de)	1987-03-18	Thienylessigsäureamidderivate und pharmazeutisch verträgliche Säureadditionssalze hiervon sowie Verfahren zu deren Herstellung
DE69311566T2 (de)	1998-01-02	Heterocyclische amine als calmodulin antagonisten
DE2416016A1 (de)	1975-09-25	Neue 1- eckige klammer auf beta-(aminocarbonylphenoxy)-aethylamino eckige klammer zu -3- (thiazol-2-oxy)-2-propanole und ihre derivate
DE2523103A1 (de)	1976-12-09	Neue propargyl-2-phenylamino-imidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben
DE1917432C2 (de)	1983-10-06	4-Hydroxythiazoline, deren Herstellung und Verwendung
DD154816B3 (de)	1987-05-13	Verfahren zur herstellung neuer pyridine
DE2053080A1 (de)	1972-05-04	N substituierte Imidazole, Ver fahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE2746550C2 (cs)	1987-10-15
DE2425767A1 (de)	1975-01-09	3-alkyl-9-aminoalkyl-1,2,3,4-tetrahydrocarbazole und ihre verwendung in arzneimitteln
DE2462966C2 (de)	1983-12-29	Derivate des 3-Amino-4-acetyl-5-methylpyrrols und diese enthaltende pharmazeutische Zubereitungen
DE2610501A1 (de)	1977-09-15	1,4-disubstituierte piperazinverbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0154721A1 (de)	1985-09-18	Neue Alkanolderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltendes Arzneimittel
DE2806654C2 (cs)	1987-07-16
DE1921453B2 (de)	1972-09-28	Basische Dithienylderivate
DE2101637A1 (de)	1971-07-22	Heterocyclische Verbindungen und Verfahren zu deren Herstellung